Provides cost-effective, high-quality low‑molecular‑weight heparin (LMWH) therapies for venous thromboembolism (VTE) prophylaxis and deep vein thrombosis (DVT) treatment. Delivers end-to-end R&D, manufacturing and commercialization capabilities to patients and pharmaceutical partners.